Immunotherapy boosts chemo against tough childhood cancer
NCT ID NCT07688252
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This pilot study tests whether adding an immunotherapy drug called dinutuximab-beta to standard chemotherapy is safe and effective for people aged 1 to 30 with newly diagnosed high-risk neuroblastoma. Dinutuximab-beta is an antibody that latches onto neuroblastoma cells, helping the immune system attack them. The study will monitor side effects and measure how much tumors shrink before the next phase of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dinutuximab-beta (an antibody that targets neuroblastoma cells) plus standard chemotherapy
- What this could lead to
- If successful, this combination could become a new standard approach to shrink high-risk neuroblastoma tumors before consolidation therapy, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early-phase pilot study, so results may not generalize. The added immunotherapy could increase side effects like allergic reactions, nerve damage, or breathing problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital Linkou Branch
Taoyuan, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Taiwan University Hospital
Taipei, Taiwan, 110, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody combo shows promise in tough childhood cancer
- Experimental cancer therapy targets tough tumors with radioactive precision
- New vaccine aims to train immune system to attack childhood cancer
- New drug combo shows promise against childhood cancer
- New hope for kids with tough cancer: drug combo trial launches
- Promising combo targets Hard-to-Treat childhood cancers